The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL

Breast-implant associated anaplastic large cell lymphoma (BIA-ALCL) is an increasingly recognized diagnosis and is described in the WHO classification (2017).1 We present a case of disease with local infiltration managed with neo-adjuvant brentuximab vedotin (BV) monotherapy leading to a complete radiological response enabling successful complete excision with considerably less extensive surgery than initially anticipated. The patient remains in remission 18 months post-operatively.